Literature DB >> 2318962

Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes.

J J Machiels1, M A Somville, P M Lebrun, S J Lebecque, M G Jacquemin, J M Saint-Remy.   

Abstract

Antigen-antibody complexes were made from allergens of the common house dust mite, Dermatophagoides pteronyssinus (Dpt) and an excess of purified autologous specific antibodies. These complexes have been used to treat Dpt-hypersensitive patients who suffered from chronic bronchial asthma. Clinical symptoms and medication intake were followed by filling in diary cards. Peak expiratory flow, measured four times a day, was also followed. Intradermal skin tests and bronchial challenge tests were performed with allergen together with an evaluation of nonspecific bronchial reactivity. Specific IgE and IgG antibodies were assayed after separation from the bulk of serum immunoglobulins by immunoadsorption. The study was carried out over two years according to a double-blind protocol. Intradermal inoculation of antigen-antibody complexes resulted in a marked reduction of both clinical and medication scores. No systemic side-effects were observed and only mild wheal and flare reactions were noted at the injection site. The treatment showed a drastic reduction of specific skin and bronchial reactivities with only marginal effects on nonspecific bronchial reactivity. Concentrations of specific IgE antibodies decreased significantly during the first weeks of treatment and remained at these lower values throughout the study. Specific IgG antibodies actually decreased in the majority of treated patients. The total amount of allergen used in this study was less than 1% of the amount currently used for conventional hyposensitization with the same allergen. These findings show that antigen-antibody complex inoculation is an efficient and safe means of treating allergic bronchial asthma and that the mechanism of action is likely to differ from conventional hyposensitization.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318962      PMCID: PMC296531          DOI: 10.1172/JCI114532

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Antigen-antibody complexes elicit anti-idiotypic antibodies to self-idiotopes.

Authors:  G G Klaus
Journal:  Nature       Date:  1978-03-16       Impact factor: 49.962

2.  Identification of gamma-E-antibodies as a carrier of reaginic activity.

Authors:  K Ishizaka; T Ishizaka
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

3.  A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies.

Authors:  L M Lichtenstein; P S Norman; W L Winkenwerder
Journal:  Ann Intern Med       Date:  1971-11       Impact factor: 25.391

4.  Measurements of responsiveness in bronchoprovocation testing.

Authors:  J E Fish; J F Kelly
Journal:  J Allergy Clin Immunol       Date:  1979-12       Impact factor: 10.793

5.  Association of asthma with serum IgE levels and skin-test reactivity to allergens.

Authors:  B Burrows; F D Martinez; M Halonen; R A Barbee; M G Cline
Journal:  N Engl J Med       Date:  1989-02-02       Impact factor: 91.245

6.  The role of antigen-antibody complexes in generating immunological memory and auto-antiidiotypic immunity.

Authors:  G G Klaus
Journal:  Adv Exp Med Biol       Date:  1979       Impact factor: 2.622

7.  Determinants of allergen-induced asthma: dose of allergen, circulating IgE antibody concentration, and bronchial responsiveness to inhaled histamine.

Authors:  D W Cockcroft; R E Ruffin; P A Frith; A Cartier; E F Juniper; J Dolovich; F E Hargreave
Journal:  Am Rev Respir Dis       Date:  1979-11

8.  IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy.

Authors:  L M Lichtenstein; K Ishizaka; P S Norman; A K Sobotka; B M Hill
Journal:  J Clin Invest       Date:  1973-02       Impact factor: 14.808

9.  Solid phase radioimmunoassay for quantitation of antigen-specific IgG in human sera with 125I-protein A from Staphylococcus aureus.

Authors:  R G Hamilton; A K Sobotka; N F Adkinson
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

10.  Suppression of reaging antibody formation. IV. Suppression of reaginic antibodies to penicillin in the mouse.

Authors:  W Y Lee; A H Sehon
Journal:  J Immunol       Date:  1976-09       Impact factor: 5.422

View more
  8 in total

Review 1.  Immunotherapy for food allergies. Past, present, future.

Authors:  S B Lehrer; L G Wild; K L Bost; R U Sorensen
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Specific immunotherapy in house dust mite allergy.

Authors:  J Bousquet; A Des Roches; L Paradis; H Dhivert; F B Michel
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

3.  Cohabiting with domestic mites.

Authors:  I H Feather; J A Warner; S T Holgate; P J Thompson; G A Stewart
Journal:  Thorax       Date:  1993-01       Impact factor: 9.139

Review 4.  Novel approaches in immunotherapy.

Authors:  J M Saint-Remy
Journal:  Clin Rev Allergy       Date:  1994

5.  Inhibition of immunoglobulin E synthesis through Fc gammaRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking.

Authors:  Jutta Horejs-Hoeck; Andrea Hren; Geert C Mudde; Maximilian Woisetschläger
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

Review 6.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 7.  2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.

Authors:  Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh
Journal:  J Allergy Clin Immunol       Date:  2020-12       Impact factor: 10.793

8.  Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: a preliminary report.

Authors:  Dong-Ho Nahm; Su-Mi Cho; Myoung-Eun Kim; Yeo-Jin Kim; Sook-Yeong Jeon
Journal:  Allergy Asthma Immunol Res       Date:  2013-10-08       Impact factor: 5.764

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.